Seigel.cv.doc

CURRICULUM VITAE

Paul H. Seigel, M.D., F.A.C.C.
Date of Birth:
Marital Status: Married

PROFESSIONAL AFFILIATION:
Baptist Hospital of Miami

CURRENT LICENSE:

EDUCATION:

Medical College of Virginia
State University of New York at Binghamton
POST GRADUATE TRAINING:
Fellowship in Cardiovascular Medicine
College of Medicine and Dentistry of New Jersey
Residency in Internal Medicine
Page Two
Paul H. Seigel, M.D., F.A.C.C.
POST GRADUATE TRAINING CONTINUED.
Internship in Internal Medicine

INVESTIGATIONS - RESEARCH:
Cardiovascular Research Center of South Florida INVEST (Knoll Pharmaceuticals). Principal Investigator. This is an
international clinical trial comparing a calcium antagonist (Verapamil
Sinus rhythm) with a non-calcium antagonist treatment strategy
(Atenolol) for the control of hypertension in patients with coronary
artery disease.
T.N.T. (Treating to New Targets) Parke-Davis/Pfizer. Principal
Investigator. This study is to assess the CHD event reduction efficacy
and safety of low-density lipoprotein cholesterol lowering to achieve
LDL-C targets beyond currently recommended minimums when
compared to only achieving the minimum.
Drug Used: Atorvistatin 10 mg up to 80 mg in the double-blind CAMELOT (Pfizer, Inc). Principal Investigator. Comparison of
Amlodipine versus Enalapril to Limit Occurrences of Thrombosis.
GUSTO IV (Eli Lily and Co). Principal Investigator. This is a post-
MI study through the Cleveland Clinic.
BRAVO: Blockade of the GP IIB/IIA Receptor to Avoid Vascular
Occlusion. Principal Investigator.
PRESTO: Prevention of REStenosis by Tranilast and its Outcomes.
Principal Investigator. A phase III Double blind Placebo Controlled
Trial of three doses of Tranilast (Protocol 004).
MOXON TRIAL (Covance). Principal Investigator.
STARSHIP (AstraZeneca) A 6 week, Randomized, open-Label,
Comparative Sturdy to Evaluate the Efficacy and Safety of
Rosuvastatin and Atirvastatin in the Treatment of
Hypercholesterolemia in Hispanic Subjects.
Page Three
Paul H. Seigel, M.D., F.A.C.C.
INVESTIGATIONS – RESEARCH (continued):

ACTIVATE (SankyoPharma Development) A Randomized,
Double-Blind placebo Controlled Study of the Efficacy and Safety of
the ACAT inhibitorCS-505 versus Placebo for Reducing the
Progression of Atherosclerosis in Subjects with Known Coronary
Artery Disease Using Ultrasound (IVUS).
EVEREST (Otsuka Pharmaceuticals) A Randomized, Double-blind
Placebo-controlled Study to Evaluate the Long Term Efficacy and
Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with
Worsening Congestive Heart Failure.
CHARISMA (Sanofinsynthelabo and Bristal Myers Squibb Co.)
Clopidogrel For High Atherothrombotic Risk and Ischemic
Stabilization, Management and Avoidance.
CP-529, 414 (Pfizer) A Randomized, Double-blind Study to
Evaluate the Efficacy, Safety, and Tolerability of Fixed Combination
CP-529,414/Atorvastatin in Patients with Angiographically
Documented Coronary Artery Disease.
LUNAR (AstraZeneca) A 12-Week, Randomized, Open-Label, 3-
Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the
Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of
Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes.
NEB 302 (Bertek Pharmaceuticals) A Double-blind, Multi-Center,
Randomized, Placebo-Controlled, Parallel Group Dosing Study
Evaluating the Effects of Nebivolol on Blood Pressure in Patients with
Mild to Moderate Hypertension.
NEB 306 (Bertek Pharmaceuticals) A Multi-Center, Parallel Group
Extension Study to Determine the Safety and Efficacy of Long-Term
Nebivolol Exposure in Patients with Mild to Moderate Hypertension.
NEB 323 (Bertek Pharmaceuticals) A Multi-Center, Open Extension
Study to Assess the Safety and Efficacy of Long-Term Nebivolol
Exposure in Patients with Mild to Moderate Hypertension.
COMPELL (Kos Pharmaceuticals) An Open-Label, Comparative
Efficacy Evaluation of Lipid Levels when Treated with Niaspan and
Statin or Other Lipid-Modifying Therapies.
Page Four
Paul H. Seigel, M.D., F.A.C.C.
INVESTIGATIONS – RESEARCH (continued):

MDT3-003 (Labopharm) A Four-Arm Study Comparing the
Analgesic Efficacy and Safety of Tramadol HCl Once a day 100, 200
and 300 mg Versus Placebo for the Treatment of Pain due to
Osteoarthritis of the Knee.

CERTIFICATIONS AND EXAMS:
Diplomate of the American Board of Internal Medicine - Diplomate of the American Board of Cardiovascular Medicine - Diplomate of National Board of Medical Examiners -
PRIVATE PRACTICE EXPERIENCE:
James Bierfeld, M.D.
Solo Practice
Associates in Cardiology
Miami Cardiology Group
Managing Partner

PROFESSIONAL ORGANIZATIONS:
REFERENCES:

Source: http://miamicardiology.net/images/uploaded/mcg/Seigel.pdf